EUnetHTA Joint Action 3 (2016-2021)

Home  /  EUnetHTA Joint Action 3 (2016-2021)

This is the second pharmaceutical Rapid Collaborative Review (PTRCR18) published by EUnetHTA. This report describes dexamethasone for the treatment of COVID-19 patients. In September, 2020, the European Commission endorsed the use of dexamethasone for the treatment of COVID-19 patients on oxygen

EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We

In June, 2020, the European Commission granted marketing authorisation for Veklury® (remdesivir) for the treatment of Covid-19. This is the first update on the pharmaceutical Rapid Collaborative Review (PTRCR15) for – Remdesivir for the treatment of COVID-19. Following the original Rapid Collaborative

EUnetHTA deems patient involvement very important in the production of Joint Assessment reports. We recognise that patients and those who support them have unique knowledge about what it is like to live with a specific disease or medical condition. We

​​This is the pharmaceutical Joint Assessment PTJA14 – Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In August, 2020, the European Commission granted marketing